Management of Escitalopram-Associated Liver Injury

Monitoring and Dose Adjustment

The American College of Clinical Pharmacology recommends obtaining baseline liver function tests (ALT, AST, alkaline phosphatase, total bilirubin) before initiating escitalopram in patients with pre-existing liver disease or risk factors 1, 2
For patients with hepatic impairment, the recommended dose is reduced to 10 mg/day 1, 2

If ALT/AST >3× ULN, immediately discontinue escitalopram and monitor liver function tests every 1-2 weeks until normalization 1, 2
If ALT/AST 1-3× ULN, consider discontinuation, monitor every 1-2 weeks, and evaluate for alternative causes 1, 2
Most cases are reversible upon discontinuation, with rapid resolution of clinical symptoms and normalization of liver enzymes typically within 2-8 weeks 1
Document the reaction as a potential drug allergy and avoid rechallenge with escitalopram 1

Do not continue escitalopram if ALT/AST rises above 3× ULN, as this indicates significant hepatocellular injury requiring immediate discontinuation 1, 2
Do not overlook other causes of elevated liver enzymes, including viral hepatitis, alcohol use, metabolic dysfunction-associated steatotic liver disease (MASLD), or concomitant hepatotoxic medications 1, 2, 3
Do not rechallenge with escitalopram after documented hepatotoxicity, as this may result in more severe or rapid recurrence of liver injury 1